TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1

PHASE2UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 31, 2004

Conditions
HIV Infections
Interventions
DRUG

TNX-355

Trial Locations (15)

20009

Dupont Circle Physicians Group, Washington D.C.

21201

Chase-Brexton Health Services, Inc., Baltimore

21205

Johns Hopkins University School of Medicine, Baltimore

32701

IDC Research Initiative, Altamonte Springs

33136

University of Miami, Miami

33607

Comprehensive Research Institute, Tampa

34205

Bach and Godofsky, Bradenton

45267

University of Cincinnati Medical Center, Cincinnati

70115

Brobson Lutz, MD, LLC, New Orleans

77025

Tanox, Inc., Houston

85006

Body Positive, Phoenix

90022

Altamed Corporation, Los Angeles

90048

Tower ID Medical Associates, Los Angeles

M4N3M5

Sunnybrook Health Science Centre, Toronto

00909

Clinical Research Puerto Rico, Inc., San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Tanox

INDUSTRY

NCT00089700 - TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1 | Biotech Hunter | Biotech Hunter